The higher rate of PD-L1 negative tumors—particularly in our 2L+ cohort—may explain part of the difference as the efficacy of immune-checkpoint inhibitors in mesothelioma does report some correlation with PD-L1 expression.1 Here, CD274 is linked to mesothelioma.